Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Emerging measurements for tumor-infiltrating lymphocytes in breast cancer.Japanese journal of clinical oncology · 2024
   Review
2. The changing face of circulating tumor DNA (ctDNA) profiling: Factors that shape the landscape of methodologies, technologies, and commercialization.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023
   Article
3. Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.Cancers · 2023
   Review
4. Molecular Biomarkers in Cancer.Biomolecules · 2022
   Review
5. Use of Routine Health Datasets to Assess the Appropriateness of Diagnostic Tests in the Follow-Up of Breast Cancer Patients: A Population-Based Study on 3930 Patients.Risk management and healthcare policy · 2022
   Article
6. Great future or greedy venture: Precision medicine needs philosophy.Health science reports · 2021
   Review
7. Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.Cancers · 2021
   Review
8. Circulating tumor cell profiling for precision oncology.Molecular oncology · 2021
   Review
9. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.NPJ breast cancer · 2020
   Review
10. Current and future perspectives of liquid biopsies in genomics-driven oncology.Nature reviews. Genetics · 2019
    Review
11. Drug-adapted cancer cell lines as preclinical models of acquired resistance.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
12. A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles.Theranostics · 2019
    Article

Corrections and comments

• Commented on by
  Analytical Validity and Clinical Utility of Tumor Biomarkers.2018
• Comment on
  Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.2018
• Comment on
  Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as